"We are excited to launch a realigned and upgraded discovery service offering for our customers through our new center for global drug discovery in Buffalo," said Christopher Conway, senior vice president, Discovery and Development, AMRI. "AMRI is the only North American based Discovery CRO with biology, pharmacology, HTS and chemistry located in one building, in the center of a hub of complimentary biotech, major medical and academic centers. This drug discovery hub provides our customers and partners with the speed in decision-making and depth of collaboration need to accelerate speed of data and maximize results."
AMRI's HTS capabilities include compound and sample management, conventional and next-generation HTS and access to equipment and readout instruments such as PerkinElmer's cell::explorer high content screening platform, and Opera Phenix high content screening system, which provides a combination of biologically relevant readouts and throughput.
AMRI has partnered with New York State as a founding member of the Buffalo Medical Innovation and Commercialization Hub (BMIC). This hub combines academic and industrial partners, creating opportunities for new collaborations to develop new approaches.
"The aim of the hub is to create a translational science center that will leverage the infrastructure of partner institutions, including SUNY Polytechnic Institute, the University at Buffalo School of Medicine, University at Buffalo Clinical and Translational Research Center, Buffalo General Hospital, Jacobs Institute, Roswell Park Cancer Institute, and the Hauptman Woodward Institute," Mr. Conway said.
